Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome

A 41-year-old woman developed nephrotic syndrome at the age of 32 and was diagnosed with minimal change nephrotic syndrome based on a renal biopsy. Although remission was achieved with administration of prednisolone (PSL) and cyclosporine, the nephrotic syndrome recurred. She was also started on rit...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, Mayuko, Sugiura, Hidekazu, Iwatani, Yosuke, Kyoda, Mizuki, Nokiba, Hirohiko, Amemiya, Nobuyuki, Nitta, Kosaku, Tsuchiya, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425356/
https://www.ncbi.nlm.nih.gov/pubmed/30956827
http://dx.doi.org/10.1155/2019/3580941
Descripción
Sumario:A 41-year-old woman developed nephrotic syndrome at the age of 32 and was diagnosed with minimal change nephrotic syndrome based on a renal biopsy. Although remission was achieved with administration of prednisolone (PSL) and cyclosporine, the nephrotic syndrome recurred. She was also started on rituximab (RTX). She developed late-onset neutropenia after RTX treatment (R-LON) and improved 17 days later. Although the majority of R-LON cases undergo spontaneous remission, cases of death have been reported. This report is intended to warn about R-LON, since the use of RTX for adult-onset nephrotic syndrome is expected to increase in the future.

Ejemplares similares